Literature DB >> 25202054

LLW-3-6 and celecoxib impacts growth in prostate cancer cells and subcellular localization of COX-2.

Tokunbo Yerokun1, Leyte L Winfield2.   

Abstract

The proliferation in human prostate carcinomas, PC3 and MDA-PCa-2b, was analyzed for cells treated with LLW-3-6 and celecoxib in the presence and absence of sulfasalazine. LLW-3-6 was more potent than celecoxib at mediating a dose-dependent reduction of viable PC3 cells. Co-treatment with a non-lethal dose of sulfasalazine diminished the potency of both drugs in this cell line. The effects of the drugs in MDA-PCa-2b cells were less significant than those observed in the PC3 cells. Localization of COX-2 in LLW-3-6- and CBX-treated PC3 cells is consistent with protein aggregation known for cells responding to stress stimuli. To complement this, an analysis of the theoretical binding interactions of LLW-3-6 was completed to illustrate the potential of LLW-3-6 to bind to COX-2 in a manner similar to that of celecoxib. Studies to further define the mechanism of action for LLW-3-6 are ongoing. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Benzimidazole; COX-2; MDA-PCa 2b; PC3; celecoxib; docking; focal adhesion; prostate cancer; sulfasalazine

Mesh:

Substances:

Year:  2014        PMID: 25202054      PMCID: PMC4204802     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

Review 1.  Glutamate and the biology of gliomas.

Authors:  John de Groot; Harald Sontheimer
Journal:  Glia       Date:  2010-12-29       Impact factor: 7.452

2.  Celecoxib for the prevention of colorectal adenomatous polyps.

Authors:  Nadir Arber; Craig J Eagle; Julius Spicak; István Rácz; Petr Dite; Jan Hajer; Miroslav Zavoral; Maria J Lechuga; Paola Gerletti; Jie Tang; Rebecca B Rosenstein; Katie Macdonald; Pritha Bhadra; Robert Fowler; Janet Wittes; Ann G Zauber; Scott D Solomon; Bernard Levin
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

3.  Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.

Authors:  Jean Y Tang; Michelle Aszterbaum; Mohammad Athar; Franco Barsanti; Carol Cappola; Nini Estevez; Jennifer Hebert; Jimmy Hwang; Yefim Khaimskiy; Arianna Kim; Ying Lu; Po-Lin So; Xiuwei Tang; Michael A Kohn; Charles E McCulloch; Levy Kopelovich; David R Bickers; Ervin H Epstein
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

4.  Lung cancer chemoprevention with celecoxib in former smokers.

Authors:  Jenny T Mao; Michael D Roth; Michael C Fishbein; Denise R Aberle; Zuo-Feng Zhang; Jian Yu Rao; Donald P Tashkin; Lee Goodglick; E Carmack Holmes; Robert B Cameron; Steven M Dubinett; Robert Elashoff; Eva Szabo; David Elashoff
Journal:  Cancer Prev Res (Phila)       Date:  2011-07

5.  LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.

Authors:  J Alegre-Abarrategui; O Ansorge; M Esiri; R Wade-Martins
Journal:  Neuropathol Appl Neurobiol       Date:  2007-10-26       Impact factor: 8.090

6.  Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.

Authors:  Herman A Perroud; Maria José Rico; Carlos M Alasino; Francisco Queralt; Leandro E Mainetti; Stella M Pezzotto; Viviana R Rozados; O Graciela Scharovsky
Journal:  Future Oncol       Date:  2013-03       Impact factor: 3.404

Review 7.  Paxillin interactions.

Authors:  C E Turner
Journal:  J Cell Sci       Date:  2000-12       Impact factor: 5.285

Review 8.  Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.

Authors:  Todd W Miller; Brent N Rexer; Joan T Garrett; Carlos L Arteaga
Journal:  Breast Cancer Res       Date:  2011-11-01       Impact factor: 6.466

9.  Ultrastructural localization of cPLA2 in unstimulated and EGF/A23187-stimulated fibroblasts.

Authors:  G Bunt; J de Wit; H van den Bosch; A J Verkleij; J Boonstra
Journal:  J Cell Sci       Date:  1997-10       Impact factor: 5.285

10.  Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Malcolm D Mason; Noel W Clarke; John Anderson; David P Dearnaley; John Dwyer; Gordana Jovic; Alastair W S Ritchie; J Martin Russell; Karen Sanders; George N Thalmann; Gianfilippo Bertelli; Alison J Birtle; Joe M O'Sullivan; Andrew Protheroe; Denise Sheehan; Narayanan Srihari; Mahesh K B Parmar
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

View more
  3 in total

1.  Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine.

Authors:  Tokunbo Yerokun; Leyte L Winfield
Journal:  Anticancer Res       Date:  2015-12       Impact factor: 2.480

2.  TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer.

Authors:  Huimin Sun; Lei Zhang; Changhong Shi; Peizhen Hu; Wei Yan; Zhe Wang; Qiuhong Duan; Fan Lu; Lipeng Qin; Tao Lu; Juanjuan Xiao; Yingmei Wang; Feng Zhu; Chen Shao
Journal:  Oncotarget       Date:  2015-05-20

3.  Long Non-Coding RNA (lncRNA) RAMS11 Promotes Metastatis and Cell Growth of Prostate Cancer by CBX4 Complex Binding to Top2α.

Authors:  Zhixiong Zheng; Kaiyan Qiu; Weiwen Huang
Journal:  Cancer Manag Res       Date:  2021-02-02       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.